PT Lippo Karawaci Tbk (PTLKF) Fair Value & Analysis
Healthcare · US · Market cap $35.4M
PT Lippo Karawaci Tbk
PTLKF · US
Fair value as of: Aug 2, 2026
From 9 valuation models · updated 8 days ago
Below-average quality, and screening another 23% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0077). The favourable scenario is already priced in.
- Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.
How to read this chart
60‑month range $0.0010 – $0.0785 · the $0.0100 price screens above the $0.0077 fair value. Dashed = 300-day average. As of Aug 2, 2026.
Analysis
PT Lippo Karawaci Tbk (PTLKF) currently trades at $0.0100, while our model-based Fair Value estimate is $0.0077, implying the stock looks roughly 23.0% overvalued today. The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Lippo Karawaci Tbk generated revenue of $7.4T at a net margin of 4.7%. Revenue declined 12.7% year over year. It earns a return on equity of 1.5%. Net debt stands at $7.7T. Fundamentals as of Aug 2, 2026
The share trades about 17% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -23%, PTLKF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 9 models by family
Widest divergence: Asset-Based ($103.51) versus Dividend Discount ($0.0036). Highest evidence: Residual Income (76).
Notify me when PTLKF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 22 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Lippo Karawaci Tbk engages in real estate development, healthcare and lifestyle businesses in Indonesia. The company is also involved in investment, development, trading, home care, and financing activities; installation and water treatment; town management; urban development; marketing and building management; clean water and waste management; hotel …
Full company description
PT Lippo Karawaci Tbk engages in real estate development, healthcare and lifestyle businesses in Indonesia. The company is also involved in investment, development, trading, home care, and financing activities; installation and water treatment; town management; urban development; marketing and building management; clean water and waste management; hotel management; catering service; and provision of accommodation and burial services. PT Lippo Karawaci Tbk founded in 1990 and is based in Tangerang, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Lippo Karawaci Tbk reported revenue of $8.9T in FY2025 versus $16.1T in FY2021, a compound −13.9%/yr. Reported net income was $471B in FY2025.
of which total revenue +2.1 pp · buybacks/dilution −6.9 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
PTLKF screens 23% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Lippo Karawaci Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Lippo Karawaci Tbk (PTLKF) overvalued or undervalued?
What is the fair value of PTLKF?
What is the quality score of PTLKF?
What is the revenue of PT Lippo Karawaci Tbk (PTLKF)?
What is the net profit margin of PTLKF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Lippo Karawaci Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.